- Maintenance olaparib is effective and well tolerated in a real-world setting in BRCA-positive patients with recurrent platinum-sensitive ovarian cancer.
- Patients with complete response after the last platinum therapy or normal Ca125 at baseline have longer PFS.
Why this matters
- Postprogression data suggest cross resistance with chemotherapy and need further evaluation.
- 234 consecutive BRCA-mutated patients with recurrent platinum-sensitive ovarian cancer (median age, 53.2 years) treated with olaparib between 2015 and 2019.
- Funding: None disclosed.
- Patients received ≥2 previous lines of platinum treatment.
- Median follow-up, 15.5 months.
- Median duration of treatment, 8.5 months.
- Overall response rate (ORR), 46.3%.
- Median PFS, 14.7 (95% CI, 12.60-18.03) months.
- PFS was statistically longer in patients with normal serum Ca125 at baseline (Ca125, ≤35 vs >35 UI/mL; 25.5 vs 7.9 months; HR, 2.5; P=.001).
- Patients who achieved complete response after last platinum-based therapy showed a statistically significant longer PFS vs those who achieved partial response (HR, 3.0; P=.001) or stable disease (HR, 2.7; P=.017).
- Most common grade 3-4 toxicity: anemia (6%).
- Of 66 evaluable patients who progressed and received further treatment, ORR was 22.2%, 11.1%, and 9.5% in patients with a platinum-free interval of >12, 6-12, and
- Retrospective analysis.